InterMune To Present At JMP Securities Healthcare Conference

         InterMune To Present At JMP Securities Healthcare Conference

PR Newswire

BRISBANE, Calif., July 2, 2013

BRISBANE, Calif., July 2, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN)
today announced that Dan Welch, Chairman, Chief Executive Officer and
President of InterMune, will present at the JMP Securities Healthcare
Conference in New York City on July 9, 2013, at 1:30 p.m. EDT.


To access a live audio webcast of the presentation, investors and other
interested parties may log on to the investor relations page of InterMune's
corporate website at The company recommends logging on to
the site 15 minutes prior to the start of the presentation in order to
register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and
commercialization of innovative therapies in pulmonology and orphan fibrotic
diseases. In pulmonology, the company is focused on therapies for the
treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung
disease. Pirfenidone, the only medicine approved for IPF anywhere in the
world, is approved for marketing by InterMune in the EU and Canada as Esbriet®
and is currently in a Phase 3 clinical trial to support regulatory
registration in the United States. InterMune's research programs are focused
on the discovery of targeted, small-molecule therapeutics and biomarkers to
treat and monitor serious pulmonary and fibrotic diseases. For additional
information about InterMune, please visit

SOURCE InterMune, Inc.

Contact: Jim Goff, InterMune, Inc., 415-466-2228,
Press spacebar to pause and continue. Press esc to stop.